PROGRAM OVERVIEW

This PhD program in Biology is led by Professor Wei-Guo Zhu, Dean of the Shenzhen University School of Medicine. This cross-disciplinary program will ensure that students are familiar with scientific frontiers in the life sciences, and gain theoretical knowledge, professional experience in biological techniques used in the research laboratory setting and science-based critical thinking. Graduates of this program will have the ability to undertake independent research and work creatively in the field of biomedical science.

Main research fields:

1. Biochemistry and Molecular Biology

Students will study the structure and function of biological macromolecules such as nucleic acids and proteins; explore the biochemical basis and regulatory mechanisms of cell metabolism and homeostasis; and make scientific breakthroughs in the fields of genomic homeostasis, the molecular mechanisms of autophagy, and the pathogenic mechanisms and early diagnosis of major diseases. The mentors in this subprogram have made many breakthroughs in above-mentioned areas and thus are internationally competitive and renowned.

2. Cancer Biology

Students will focus on the biological basis of DNA replication, DNA damage repair, cancer chemoradiotherapy and immunotherapy, and the molecular mechanisms underlying the tumor microenvironment regulating pancreatic cancer metastasis; interpret the molecular mechanisms of maintaining genomic stability; explore new carcinogenic mechanisms and cancer therapeutic targets; and develop new anticancer lead compounds. The mentors in this subprogram are world renowned experts who have  published numerous original research papers in high-profile international journals such as Molecular Cell, Cell Research, and PNAS. In addition, they continuously host an international conference series on DNA repair.

CORE COURSES

Frontiers in Life Science, Academic and Professional English, Biochemistry and Molecular Biology, Advanced Cell Biology and Disease, Cancer Biology

CAREER PROSPECTS

Graduates will be able to follow careers in the biomedical sciences for both academic and industry.

Consultation

Email: molmed.hsc@szu.edu.cn                  

英文名

SHUNICHI TAKEDA

联系邮箱

stakeda@szu.edu.cn

中文简介

武田教授的实验室主要研究抗癌药物的分子机制。我们的研究目标是提供一种可预测不同抗癌疗法对不同癌症患者治疗疗效的情况，并为每个患者提供最佳的治疗。每个患者的癌症特征都有很大的不同，例如，每个癌基因的活性和抗癌治疗的疗效在每个乳腺癌患者之间都有很大的不同。在不久的将来，有可能可以确定每个恶性肿瘤病人中许多基因的活性状态。抗癌药物会杀死循环中的正常细胞，产生非常严重的副作用。因此，在实际治疗前预测抗癌药物的疗效和副作用的发生是非常重要的。武田教授的实验室一直致力于干扰人类癌细胞中的基因研究，并检测每个基因的活性对抗癌药物疗效的影响。本研究将有助于通过分析恶性肿瘤中基因的活性状态来预测不同疗法的疗效。这项研究也让学生系统地学习基因研究的方法，包括基因破坏和基因破坏细胞的许多表型分析，与大家分享更多基因的突变细胞进行科学研究。

英文简介

Prof. Takeda’s laboratory has investigated molecular mechanisms underlying anti-cancer drugs. The goal of our study is to develop the method of predicting the efficacy of various anti-cancer therapies on individual cancer patients and to offer the best therapy to each patient. The character of cancers arising in each patient significantly vary, for example, each oncogene’s activity and the efficacy of anti-cancer therapies are very different from one breast cancer patient to another. It is possible in the near future to determine the activity status of many genes in each patient’s malignant tumor. Anti-cancer drugs kill actively cycling normal cells causing very severe side effects. Thus, it is very important to anticipate the efficacy of anti-cancer drugs and the occurrence of side effects before actual treatments. Prof. Takeda’s laboratory has been disrupting genes in human cancer cells and examining the effect of each gene’s activity on the efficacy of anti-cancer drugs. This study will contribute to the prediction of different therapies’ efficacy by analyzing the activity status of genes in malignant tumors. This study also allows students to systematically learn methods of the genetic study, including gene disruption and many phenotypic analyses of gene-disrupted cells, sharing mutant cells of many genes with colleagues.

英文名

XU, Xingzhi

联系邮箱

Xingzhi.Xu@szu.edu.cn

中文简介

以诚为本赢在信誉9001cc特聘教授、医学部副主任，国际先进材料协会（IAAM）会士，《Genome Instability & Disease》常务主编、中国细胞生物学学会细胞信号转导分会副会长（2015-2023）。长期致力于DNA损伤应答、DNA复制及复制应激、基因组稳定性维持的研究，并开发靶向基因组稳定性的抗癌先导化合物。在国际主流杂志发表SCI论文100余篇；主编《肿瘤生物学导论》（科学出版社，2014）。2011年创建DNA损伤应答北京市重点实验室并任主任（2011-2017）；2010年创办并连续主办DNA损伤应答与人类疾病国际研讨会（isDDRHD）年会系列并成为有国际影响力的品牌会议，是中国DNA修复领域的核心召集人。

英文简介

Distinguished Professor of Shenzhen University, Vice Dean of School of Medicine, Fellow of the International Association for Advanced Materials (IAAM), Deputy Editor-in-chief of Genome Instability & Disease, Vice President of Chinese Society for Cell Signal Transduction, CSCB (2015-2023). He has long been devoted to the research of DNA damage response, DNA replication and replication stress response, and maintenance of genome stability, and has developed anticancer lead compounds targeting genome homeostasis. He has published more than 100 SCI papers in international mainstream journals; edited "Principles of Cancer Biology" (Science Press, 2014). In 2011, he founded the Beijing Key Laboratory of DNA Damage Response and served as the director (2011-2017); in 2010, he founded and successively hosted the annual conference series of the international symposium on DNA Damage Response and Human Diseases (isDDRHD), which has become an internationally influential brand conference. Therefore, he becomes the core convener in the field of DNA repair in China.

英文名

Wei-Guo Zhu

联系邮箱

zhuweiguo@szu.edu.cn

中文简介

朱教授是以诚为本赢在信誉9001cc医学部特聘教授，博士生导师，医学部主任，多项科技部“973”及“863”计划负责人; 国家基金委创新团队负责人;国家基金委重大及重点项目负责人; 国家杰出青年基金获得者。

朱教授聚焦探讨组蛋白修饰酶和相关的组蛋白修饰在DNA损伤应答、细胞自噬及基因调控等过程中的功能及其在肿瘤发生发展中的作用，发现了一系列重要的肿瘤治疗新靶点和新方法，为肿瘤的精准治疗提供了重要的理论基础和实验支撑。他在国际主流期刊发表160余篇研究论文，包括Nature, Nature Cell Biology, Molecular Cell, PNAS等，被引用15000余次。学术研究主要包括以下三个方面：

1.识别一系列参与肿瘤细胞DNA损伤反应的组蛋白修饰位点/组蛋白修饰酶，为肿瘤放疗和化疗提供理论依据；

2. 揭示组蛋白修饰酶在自噬多层次调控中的生物学功能；

3.巩固了蛋白质乙酰化修饰参与肿瘤表观遗传治疗的理论基础。

英文简介

Prof. Zhu is a distinguished Professor of Shenzhen University,  and Dean of the School of Medicine, Shenzhen University, Ph.D Supervisor. He is the head of a number of "973" and "863" programs of the Ministry of Science and Technology of China,  head of the National Funding Commission’s innovation team of NSFC, head of the National Funding Commission’s key R&D program, Recipient of the National Outstanding Distinguished Youth Scientist，as well as the head of major and key projects of the National Foundation Commission of China.

Prof. Zhu focuses on the function of the histone modification enzymes and histone modification in the DNA damage response, autophagy and gene regulation, and its role in cancer development. He found a series of important new targets and methods for cancer treatment, which provides an important theoretical basis and experimental support for the accuracy of tumor therapy. He has published more than 160 research papers in leading international journals including Nature, Nature Cell Biology, Molecular Cell, and PNAS which earned more than 15,000 citations. His academic research mainly includes the following three aspects:

1. Identifying a series of histone modifications sites / histone modifying enzymes that participate in the DNA damage response of tumor cells, providing a theoretical basis for tumor radiotherapy and chemotherapy.

2. Revealing the biological functions of histone-modifying enzymes in the multi-level regulation of autophagy.

Consolidating the theoretical basis for the involvement of protein acetylation modification in tumor epigenetic therapy.

英文名

Huiqiang Lou

联系邮箱

lou@szu.edu.cn

中文简介

楼慧强实验室致力于探讨肿瘤发生的两种假说：基因组不稳定性和代谢紊乱，尤其是两个假说之间的关联。我们综合运用遗传学、生物化学、细胞生物学及系统生物学等手段，一方面研究DNA复制及其关联事件出错的原因；另一方面研究营养（糖）代谢如何影响DNA复制与基因组稳定性。近五年代表作发表在Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet 等高水平杂志。

英文简介

The Lou Group is devoted to uncover the potential crosstalk between metabolic dysregulation and genome instability, the two major resources which are considered to underlie cancer initiation. We apply multidisciplinary approaches such as genetics, biochemistry, cell biology, quantitative biology and synthetic biology to investigate DNA replication, co-replication events and whether/how sugar metabolism affects DNA replication/genome integrity. Our recent high-impact publications include Genes & Dev, EMBOJ, Cell Rep, EMBO Rep, CMLS, PLoS Genet.  

英文名

Cheng Yong-Xian

联系邮箱

yxcheng@szu.edu.cn

中文简介

程永现教授长期从事中药药效物质研究，创建了中医治则治法指导下阐明中药药效物质的新模式，形成了围绕慢性疾病运用“衷中参西”方法揭示中药药效物质的新体系，并在树脂、灵芝、昆虫三大特色中药研究方面取得突破性进展。其研究工作涉及中药化学成分分离、鉴定、活性发现及采用化学生物学方法鉴定靶标。主持（过）NSFC-云南联合基金重点项目、国家自然科学基金重点项目、十二五国家重大新药创制专项课题、十三五国家重点研发计划课题等。曾先后获云南省自然科学一等奖、广东省科技进步一等奖、中华医学科技一等奖、国家科技进步二等奖等。已发表论文300余篇、获授权专利50余件，培养硕士和博士研究生100余名。

英文简介

My research interests are on the isolation, structural characterization, biological evaluation, structural optimization, and mechanistic exploration of natural products produced by insects, Ganoderma fungi, and plant resins. Moreover, our research deals with target identification of bioactive small molecules using chemical biology approaches. I have focused on compounds with potential reno-protective and neuro-protective effects inspired by traditional Chinese medicine philosophy or bionic concepts. In particular, I made great progress on nonpeptide small molecules from the insects and aromatic meroterpenoids from Ganoderma fungi, which represents pioneering work in this field. Given these achievements, I was supported by the National Science Fund for Distinguished Young Scholars in China. My future research will utilize biotic and abiotic stressors, such as light induction, to create chemical and biological diversities of metabolites from the above materials. Under the support of projects such as National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the Eleventh and Twelfth Five-year Plan Periods, NSFC-Joint Foundation of Yunnan Province, National Natural Science Foundation of China, Knowledge Innovation Project of the Chinese Academy of Sciences, and West Light Foundation of the Chinese Academy of Sciences, I have published 300 papers (e.g. JASN, Org Lett, J Nat Prod) and applied for 50 patents. I am currently mentoring two PhD candidates and 20 MSc candidates.

英文名

Desheng Lu

联系邮箱

delu@szu.edu.cn

中文简介

吕德生教授是以诚为本赢在信誉9001cc医学部特聘教授，以诚为本赢在信誉9001cc医学部药理学系主任，深圳市孔雀计划B类人才。他的主要研究方向为肿瘤干细胞相关信号通路（包括Wnt信号通路）、肿瘤干细胞和抗肿瘤新药的研发。1998年，获得加拿大多伦多大学博士学位，迄今已发表60多篇科学论文，论文已被引用超过3400次，H-指数为27，目前担任PNAS、 Blood、 Cancer Research、Clinical Cancer Research等国际著名杂志特约审稿专家，现任深圳市分析测试协会医学测试专委会副主任委员。

英文简介

Prof. Lu is a distinguish professor and Chairman of Department of Pharmacology in Shenzhen University Health Science Center. He won the Shenzhen Peacock Talent Award (Class B). His main research interests are cancer stem cells-associated signaling transduction (especially Wnt signaling pathway), cancer stem cells and anti-cancer drug discovery. He received his doctorate in medical genetics from University of Toronto in 1998. So far, he has published more than 60 scientific papers, including many high-level articles published in some prestigious international journals. These papers have been cited more than 3400 times with an H-index of 27. He has served as a reviewer of internationally renowned journal such as PNAS, Blood, Cancer Research, and Clinical Cancer Research. He is currently the deputy chairman of the Medical Testing Committee of Shenzhen Analytical Testing Association.

英文名

Aifa Tang

联系邮箱

tangaifa2018@email.szu.edu.cn

中文简介

  从事肿瘤基因组基础与重大疾病体外诊断研究。参与发起“中国泌尿生殖系统肿瘤基因组计划”和“国际泌尿生殖系统肿瘤基因组计划”，现为国际肿瘤基因组协作组（ICGC）膀胱癌项目首席研究员（PI）和肾癌项目首席研究员（PI）。以第一作者身份在Nature Genetics封面文章发表中国第一篇实体瘤的肿瘤基因组研究论文，该文科学发现提示了肿瘤发生的“染色质重塑-肿瘤抑制”新理论，目前该文已被引用338次。第二篇Nature Genetics研究论文，其科学发现提示了肾癌发生的低氧诱导理论，目前已被引用144次。通过肾癌单细胞测序，首次建立了肿瘤单细胞测序技术体系，该研究为解释肾癌放化疗不敏感提供了直接的理论证据，该研究在Cell杂志发表，目前已被引用291次。源头发现一批与肿瘤复发及预后相关的新肿瘤基因突变；开发ctDNA膀胱癌靶向深度测序检测新方法；已完成肿瘤热点基因突变临床服务分析165例。

英文简介

Engaged in research on tumor genome foundation and in vitro diagnosis of major diseases. He participated in the launching of the "China Urogenital Cancer Genome Project" and the "International Urogenital Cancer Genome Project", and is now the chief researcher (PI) of the International Cancer Genome Cooperation Group (ICGC) bladder cancer project and the chief researcher (PI) of the kidney cancer project. As the first author, He published the first tumor genome research paper on solid tumors in China on the cover article of Nature Genetics. The scientific findings of this paper suggest a new theory of "chromatin remodeling tumor inhibition" in tumor development. Currently, this article has been cited 338 times. The second Nature Genetics research paper, whose scientific findings suggest the theory of hypoxia induction in renal cell carcinoma, has been cited 144 times so far. A tumor single cell sequencing technology system has been established for the first time through single cell sequencing of renal cancer. This study provides direct theoretical evidence for explaining the insensitivity of renal cancer to radiotherapy and chemotherapy. The study was published in Cell magazine and has been cited 291 times so far. Discovering a batch of new tumor gene mutations related to tumor recurrence and prognosis at the source; To develop a new method of ctDNA targeting depth sequencing for bladder cancer; A clinical service analysis of 165 cases of tumor hotspot gene mutations has been completed.

英文名

Liyun Gong

联系邮箱

gongly@szu.edu.cn

中文简介

  巩丽云，女，教授，医学博士,留学博士研究生导师，深圳市生物化学与分子生物学会理事，广东省医学教育协会生物化学与分子生物学专业委员会委员，美国国立卫生研究院（NIH）美国国立癌症研究所（NCI）Guest Researcher。主持和参与多项国家自然科学基金、广东省自然科学基金和深圳市自由探索等研究项目，在Clinical Cancer Research，Journal of Pathology，Cell Death&Disease、Oncogene等权威TOP期刊发表研究论文多篇。目前从事丝精氨酸蛋白激酶1（SRPK1）在非小细胞肺癌靶向药物EGFR-TKI耐药的机制研究。

学习经历

2005年9月---2008年7月  中山大学 中山医学院 微生物学博士

2000年9月---2003年7月  大连医科大学 免疫学硕士

1992年9月---1997年7月  大连医科大学 医学学士

英文简介

Liyun Gong, Doctor of Medicine, supervisor of doctoral students abroad, director of the Shenzhen Society of Biochemistry and Molecular Biology, member of the Biochemistry and Molecular Biology Professional Committee of the Guangdong Medical Education Association, and Guest Researcher of the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the United States. Led and participated in multiple research projects such as the National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation, and Shenzhen Free Exploration, and published multiple research papers in authoritative TOP journals such as Clinical Cancer Research, Journal of Pathology, Cell Death&Release, and Oncogene. Currently engaged in research on the mechanism of resistance of serine arginine protein kinase 1 (SRPK1) to the targeted drug EGFR-TKI in non-small cell lung cancer.

Education

Ø BMed(1997), Medical Laboratory, Dalian Medical University  

Ø MMed(2003), Immunology, Dalian Medical University

Ø DMed(2008), Zhongshan Medical school, Sun Yat-sen University

Research interests: Tumor metastasis, non-small cell lung cancer, kinase target drug resistance. Our study focuses on the mechanism of serine arginine protein kinase (SRPK1) promoting molecular targeted drug EGFR-TKIs resistance in non-small cell lung cancer (NSCLC). We found that the non-kinase domain of SRPK1 may play a key role in tumorigenesis indicating that SRPK1 may be a potential drug target.

英文名

Su Wen

联系邮箱

casufa@163.com

中文简介

  苏文，以诚为本赢在信誉9001cc副教授、特聘研究员，深圳市孔雀人才C类人才，研究方向为脂滴在高血压、脂肪肝、糖尿病等代谢性疾病发病过程中的调控机制，非酒精性脂肪性肝炎（NASH）新药研发。北京大学优秀毕业生，获国家博士后基金一等资助，国家自然科学基金青年基金、面上基金，深圳市基础项目等科研基金的资助。在国际上首次建立了正常人肝脏和脂肪脏的脂滴蛋白数据库，发现新型的脂滴相关蛋白HSD17B13参与人非酒精性脂肪肝和脂肪性肝炎的发生，为NASH的诊断和药物研发提供了新的靶点。在Nature commun、PNAS、Biochim Biophys Acta Mol Basis Dis、Am J Physiol Endocrinol Metab等杂志发表研究论文，Am J Physiol Endocrinol Metab.审稿人，美国糖尿病协会会员，中国生理协会青年委员、生理学报青年编委。

英文简介

Dr. Wen Su is an associate professor at the department of pathophysiology, Shenzhen University Health Science Center. She received her PH.D. degree at Peking University, China in 2014. Her research field include lipid metabolism, lipid droplet proteins, mechanisms of lipid dysregulation in metabolic diseases such as NAFLD/NASH, obesity and diabetes, Her original research about 17β-HSD13 provides a potential link between LD proteins and NAFLD. Her discovery about 17β-HSD13 was confirmed in several large-scale population GWAS studies which reveals that an insertion SNP72613567 of HSD17B13 gene represents a loss-of-function and confer a strong protective effect on liver injury, inflammation, fibrosis, cirrhosis, She has published a serious articles as the first author or corresponding author, including Nature commun，PNAS、Biochim Biophys Acta Mol Basis Dis、Am J Physiol Endocrinol Metab. et al. She is a member of Chinese Physiology Association and American Diabetes Association.

英文名

Yin Peng

联系邮箱

ypeng@szu.edu.cn

中文简介

  2010年毕业于Loyola University Chicago获生物医学博士学位。现任以诚为本赢在信誉9001cc医学部病理学系副教授。主要研究方向是胃肠道肿瘤中的非编码RNA作用机制及其相关信号通路，发表SCI一作和通讯作者论文20篇，包括 Oncogene，Molecular Cancer，Cancer Letters等。主持国家自然科学基金2项、广东省自然科学基金2项及广东省医学科学基金，深圳市基础研究，深圳高层次人才基金，以诚为本赢在信誉9001cc启动基金等多个项目，总经费超过500万。美国肿瘤学会AACR会员。深圳市孔雀C类人才。

英文简介

Dr. Yin Peng received the PhD degree in Molecular and Cellular Biochemistry from Loyola University Chicago in 2010. She is currently an associate professor in Department of Pathology at Shenzhen University, China. Her long-standing research interests lie in elucidating the molecular mechanisms of cell signaling transduction pathway underlying tumorigenesis. Her lab is actively exploring how oncogenic circRNAs regulate critical signaling transduction pathways, such as the Wnt/β -catenin pathway and NF-κB signaling pathway to promote cell survival, proliferation and migration in cancer cells. She has published over 20 first author/corresponding author papers in professional, peer-reviewed journals including Oncogene, Molecular Cancer, Cancer Letters. She is an AACR member and Shenzhen Peacock Talent C.

英文名

Bin Peng

联系邮箱

binpeng@szu.edu.cn

中文简介

彭斌，博士，以诚为本赢在信誉9001cc副教授，留学博士生导师/硕士生导师。致力于基因组不稳定性与人类疾病（如肿瘤、先天性小头畸形）方面的研究，侧重于翻译后修饰如磷酸化、泛素化协调调控DNA损伤/DNA复制胁迫应答分子机制的阐明。此外，在筛选小分子抑制剂、优化抗癌先导物和评估其生物学效应方面积攒了一定经验，在国际主流杂志Proc Natl Acad Sci U S A, Nucleic Acids Res, eLife, iScience, J Biol Chem, J Med Chem和Eur J Med Chem等发表SCI 论文21篇。主持科技部国家重点研发计划子课题、国家自然科学基金面上项目和青年项目、广东省自然科学基金项目和深圳市科技计划基础研究项目等多个科研项目。参与国家自然科学基金重大项目、重点项目及国际合作等。

英文简介

Peng Bin, Ph.D., associate professor at Shenzhen University, supervisor of Ph.D students/master students. Committed to research on genome instability and human diseases (such as tumors, congenital microcephaly), focusing on the elucidation of the molecular mechanisms of post-translational modifications such as phosphorylation and ubiquitination to coordinately DNA damage/DNA replication stress response. In addition, he has accumulated certain experience in screening small molecule inhibitors, optimizing anti-cancer leads and evaluating their biological effects. He has published 21 SCI papers in journal such as Proc Natl Acad Sci U S A, Nucleic Acids Res, eLife, iScience, J Biol Chem, J Med Chem and Eur J Med Chem, etc. He has presided over a number of scientific research projects such as sub-topics of the Ministry of Science and Technology’s National Key R&D Plan, National Natural Science Foundation General Projects and Youth Projects, Guangdong Provincial Natural Science Foundation Projects, and Shenzhen Science and Technology Plan Basic Research Projects.

英文名

Xue Liu

联系邮箱

xueliu@szu.edu.cn

中文简介

  刘雪, 以诚为本赢在信誉9001cc医学部副教授，深圳市海外高层次人才，广东省特支计划青年拔尖人才获得者。2021年8月入职以诚为本赢在信誉9001cc医学部，组建人类病原性细菌研究团队（http://xliugroup.com/）。近年发表SCI论文20余篇，其中第一作者（含共同一作）论文10篇，包括Cell Host & Microbe, Molecular Cell, Nature Protocols, Molecular Systems Biology (封面文章）等国际知名高水平期刊。首次鉴定了LafB可为广谱的链球菌菌的疫苗靶点，并获国际专利1项。

“克菌治病”课题组目前研究方向包括以下三个方面：

1）重要人类病原细菌的致病机理。

2）肠道非模式细菌的高效遗传筛选平台开发。

  3) 采用时空组学探究细菌感染关键病灶的发病机制。

英文简介

Liu Xue is an associate professor at the Medical School of Shenzhen University, a high-level overseas talent in Shenzhen, and a recipient of the Guangdong Province Special Support Program for Young Talents. In August 2021, she joined the Medical School of Shenzhen University and established the Human Pathogenic Bacteria Research Team (http://xliugroup.com/). In recent years, she has published more than 20 SCI papers, including 9 as the first author or co-first author, in internationally renowned high-level journals such as Cell Host & Microbe, Molecular Cell, Nature Protocols, and Molecular Systems Biology (cover article). She identified LafB as a target for pneumococcal vaccine develop with wide-range protection against strains with different serotypes.

Our "Fighting Bacterial Diseases" research group is currently focused on three main areas:

1) The pathogenic mechanisms of important bacterial human pathogens.

2) The development of efficient genetic screening platforms for non-model bacteria in the gut.

3) Using spatial and temporal omics to explore the pathogenesis of key lesions in bacterial infections.

英文名

Xingsheng Shu

联系邮箱

shu@szu.edu.cn

中文简介

    舒兴盛，博士，副教授，深圳市海外高层次人才（C类）。2008年于北京大学生命科学学院获学士学位，2012年于香港中文大学医学院临床肿瘤学系获博士学位，现任以诚为本赢在信誉9001cc医学部基础医学院副教授。舒兴盛博士长期致力于肿瘤中的表观遗传调控异常的机制及相关的转化治疗研究，目前共发表SCI论文三十余篇，被引用1300余次，H-index为20，其中近5年在PNAS、Oncogene、Journal of Pathology、Theranostics等高水平学术期刊以通讯或第一作者发表论文十余篇，获得中国发明专利授权两项，并主持完成多项国家和省市级项目，目前有包括国自然面上项目在内的多个项目在研。更多研究情况请参看链接：https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/。

英文简介

    Dr. Xing-sheng Shu received his B.S. degree from the School of Life Sciences, Peking University in 2008 and his Ph.D. degree from the Department of Clinical Oncology, The Chinese University of Hong Kong in 2012. He is currently an Associate Professor at the School of Medicine, Shenzhen University. Dr. Shu has been working on abnormal epigenetic and transcriptional regulation in cancer and related translational research for cancer therapy. He has published more than 30 SCI papers with more than 1300 citations and an H-index of 20, including more than 10 papers in PNAS, Oncogene, Journal of Pathology, Theranostics and other high impact journals in recent 5 years as corresponding or first author. He also holds two invention patents, and completed many national and provincial research projects. For more information about his research, please refer to the link: https://www.ncbi.nlm.nih.gov/myncbi/xingsheng.shu.1/bibliography/public/.